Beijing Science Sun Pharmaceutical Management

Management Kriterienprüfungen 2/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Biao Ma

Geschäftsführender

CN¥551.6k

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	22.9yrs
Eigentum des Geschäftsführers	49.5%
Durchschnittliche Amtszeit des Managements	keine Daten
Durchschnittliche Amtszeit der Vorstandsmitglieder	6.3yrs

Jüngste Management Updates

Recent updates

Beijing Science Sun Pharmaceutical's (SZSE:300485) Problems Go Beyond Weak Profit

Apr 16

Geschäftsführer

Biao Ma (60 yo)

22.9yrs

Amtszeit

CN¥551,600

Vergütung

Mr. Biao Ma serves as Chairman of the Board of Directors and General Manager at Beijing Science Sun Pharmaceutical Co., Ltd. He has served as a Director at Beijing Science Sun Pharmaceutical Co., Ltd. sinc...

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Biao Ma	Chairman & GM	22.9yrs	CN¥551.60k	49.51% CN¥ 1.5b
Li Ma	CFO, Deputy GM & Director	17.5yrs	CN¥519.00k	6.2% CN¥ 183.3m
Xue Feng Wang	Deputy GM	17.5yrs	CN¥413.40k	0.012% CN¥ 368.5k
Lina Zhao	Chairman of Supervisory Board	6.3yrs	keine Daten	keine Daten
Meng Wei Song	Supervisor	12.9yrs	keine Daten	keine Daten
Wentao Xu	Non-Independent Director	6.3yrs	CN¥60.00k	keine Daten
Changcheng Yin	Non-Independent Director	3.4yrs	CN¥60.00k	keine Daten
Ning Zhang	Supervisor	3.4yrs	keine Daten	keine Daten
Fei Wang	Independent Director	6.3yrs	CN¥60.00k	keine Daten
Yanheng Song	Independent Director	less than a year	keine Daten	keine Daten
Feng Liu	Independent Director	less than a year	keine Daten	keine Daten
Yunping Dai	Independent Director	less than a year	keine Daten	keine Daten

6.3yrs

Durchschnittliche Betriebszugehörigkeit

53yo

Durchschnittliches Alter

Erfahrener Vorstand: 300485Die Vorstandsmitglieder gelten als erfahren (6.3 Jahre durchschnittliche Amtszeit).

Beijing Science Sun Pharmaceutical Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Beijing Science Sun Pharmaceutical Co., Ltd., Annual General Meeting, Apr 30, 2024

Insufficient new directors

Beijing Science Sun Pharmaceutical Co., Ltd. Announces Executive Changes

Beijing Science Sun Pharmaceutical Co., Ltd., Annual General Meeting, Apr 21, 2022

Beijing Science Sun Pharmaceutical Co., Ltd. Announces Directorate Changes

Recent updates

Dividend reduced to CN¥0.022

Beijing Science Sun Pharmaceutical Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2023, Payable on 29 May 2024

First quarter 2024 earnings released: CN¥0.40 loss per share (vs CN¥0.002 profit in 1Q 2023)

Beijing Science Sun Pharmaceutical's (SZSE:300485) Problems Go Beyond Weak Profit

Investor sentiment deteriorates as stock falls 17%

Beijing Science Sun Pharmaceutical Co., Ltd., Annual General Meeting, Apr 30, 2024

Full year 2023 earnings released: EPS: CN¥0.21 (vs CN¥0.43 in FY 2022)

Beijing Science Sun Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Investor sentiment deteriorates as stock falls 17%

Insufficient new directors

Beijing Science Sun Pharmaceutical Co., Ltd. Announces Executive Changes

Beijing Science Sun Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 10, 2024

Third quarter 2023 earnings released: CN¥0.12 loss per share (vs CN¥0.037 profit in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.52 (vs CN¥0.27 in 2Q 2022)

Beijing Science Sun Pharmaceutical Co., Ltd. Announces 2022 Final Profit Distribution Plan to Be Implemented (A Shares), Payment Date of 23 May 2023

First quarter 2023 earnings released: EPS: CN¥0.002 (vs CN¥0.22 in 1Q 2022)

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥0.037 (vs CN¥0.11 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.27 (vs CN¥0.09 in 2Q 2021)

Beijing Science Sun Pharmaceutical Co., Ltd. Announces Cash Dividend for the Fiscal Year 2021, Payable on 31 May 2022

First quarter 2022 earnings released: EPS: CN¥0.22 (vs CN¥0.09 in 1Q 2021)

Beijing Science Sun Pharmaceutical Co., Ltd. Approves the Profit Distribution of Final Cash Dividend for the Year 2021

Beijing Science Sun Pharmaceutical Co., Ltd., Annual General Meeting, Apr 21, 2022

Full year 2021 earnings released: EPS: CN¥0.84 (vs CN¥0.32 in FY 2020)

Beijing Science Sun Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2021

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS CN¥0.11 (vs CN¥0.09 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.09 (vs CN¥0.14 in 2Q 2020)

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.09 (vs CN¥0.05 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.32 (vs CN¥0.31 in FY 2019)

New 90-day low: CN¥11.30

Full year 2020 earnings released: EPS CN¥0.31 (vs CN¥0.31 in FY 2019)

Beijing Science Sun Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Mar 30, 2021

Beijing Science Sun Pharmaceutical Co., Ltd. Announces Directorate Changes

New 90-day low: CN¥12.45

Investor sentiment deteriorated over the past week

New 90-day low: CN¥13.92

New 90-day low: CN¥16.02

Third quarter earnings released

Beijing Science Sun Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 28, 2020

New 90-day low - CN¥16.09

First half earnings released

Beijing Science Sun Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020

Geschäftsführer

Amtszeit

Vergütung

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter